Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alizée Viandier"'
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
Autor:
Anja Seckinger, Vanessa Buatois, Valéry Moine, Bruno Daubeuf, Françoise Richard, Laurence Chatel, Alizée Viandier, Nicolas Bosson, Emeline Rousset, Krzysztof Masternak, Susana Salgado-Pires, Claudia Batista, Christelle Mougin, Flora Juan-Bégeot, Yves Poitevin, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBlocking the CD47 “don’t eat me”-signal on tumor cells with monoclonal antibodies or fusion proteins has shown limited clinical activity in hematologic malignancies and solid tumors thus far. Main side effects are associated with non-
Externí odkaz:
https://doaj.org/article/54cec0396f744440a1e37f2a5e4704e8
Autor:
Walter Ferlin, Stéphanie Hugues, Xavier Chauchet, Elise Pernarrieta, Nicolas Bosson, Sébastien Calloud, Louis Hellequin, Margaux Legrand, Alizée Viandier, Françoise Richard, Laura Cons, Pauline Malinge, Tereza Bautzova, Jérémie Bourguignon, Guillemette Pontini, Mengzhu Sun, Ulla Ravn, Valéry Moine, Yves Poitevin, Nicolas Fischer, Limin Shang, Krzysztof Masternak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/fd883ac37182497abd025cc9848e0fb7
Autor:
Xavier Chauchet, Nicolas Bosson, Margaux Legrand, Laura Cons, Sébastien Calloud, Alizée Viandier, Françoise Richard, Pauline Malinge, Tereza Bautzova, Jérémie Bourguignon, Guillemette Pontini, Elise Penarrieta, Mengzhu Sun, Ulla Ravn, Valéry Moine, Giovanni Magistrelli, Yves Poitevin, Stéphanie Hugues, Limin Shang, Walter Ferlin, Krzysztof Masternak
Publikováno v:
Cancer Research. 82:3429-3429
PD-1/PD-L1 blockade has improved survival across many types of cancer, but only in a minority of patients. Co-targeting PD-1/PD-L1 and the CD47/SIRPα myeloid checkpoint with monoclonal antibody (mAb) combinations showed increased antitumor responses
Autor:
Nicolas Bosson, Margaux Legrand, Ulla Ravn, Stéphanie Hugues, Alizée Viandier, Krzysztof Masternak, Sébastien Calloud, Françoise Richard, Guillemette Pontini, Jérémie Bourguignon, Walter Ferlin, Louis Hellequin, Laura Cons, Xavier Chauchet, Mengzhu Sun, Elise Pernarrieta, Limin Shang, Nicolas Fischer, Valéry Moine, Pauline Malinge, Yves Poitevin, Tereza Bautzova
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPD-1/PD-L1 blockade can significantly improve survival across many types of cancer, but only in a minority of patients. To broaden its therapeutic efficacy, several combination partners are now being evaluated together with PD-1/PD-L1 block